| Molecular formula | C50H73N15O11 |
|---|
| Molecular weight | 1060.2 g/mol |
|---|
| Registered trials | 148 |
|---|
| PubChem CID | 439201 |
|---|
What bradykinin is
Bradykinin is a peptide compound with the molecular formula C50H73N15O11 and a molecular weight of approximately 1,060.2 g/mol (PubChem CID 439201). It has no FDA-approved label, and no drug product built around it has been approved for any indication. It is classified in research and clinical study contexts as an investigational and research-use compound rather than an approved therapeutic.
Trial footprint
Public registries list 148 registered clinical trials referencing bradykinin. The available trial sample spans varied contexts rather than a single therapeutic use. One registry-type study, "Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II" (NCT03828279), tracks natural history in a patient population where bradykinin pathways are studied, and its status is listed as unknown. A completed study, "Health Effects of Biodiesel Exhaust Exposure" (NCT01883466), examined exposure effects unrelated to any therapeutic claim. Another completed study, "Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3" (NCT00685945), looked at physiological system interactions. These entries reflect the range of research contexts in which bradykinin appears rather than evidence of any benefit or approved use.
FAQ
No. Bradykinin does not have an FDA-approved label or brand product. It is studied in research and clinical trial settings but is not an approved therapeutic.
Bradykinin is a peptide with the molecular formula C50H73N15O11 and a molecular weight of about 1,060.2 g/mol. It is catalogued in PubChem under CID 439201.
Public registries list 148 clinical trials referencing bradykinin. These span diverse research areas rather than a single approved or proposed therapeutic use.
Sampled studies include a hereditary angioedema natural history registry, a biodiesel exhaust exposure study, and research on the renin-angiotensin aldosterone system and fibrinolysis. These reflect varied physiological research contexts, not evidence of therapeutic efficacy.
No FAERS adverse event report data was available for bradykinin in this review. Any side effect profile would need to come from primary research literature rather than adverse event databases.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 439201 ClinicalTrials.gov registry data NCT03828279 NCT01883466 NCT00685945
Updated 2026-08-10